细胞DNA倍体分析系统结合HR-HPV在宫颈癌筛查中的应用  

Application of HR-HPV Combined With Cell DNA Ploidy Analysis System in Cervical Cancer Screening

作　　者：王建 黄种心[1] WANG Jian;HUANG Zhongxin(Department of Pathology,The Second Affiliated Hospital of Fujian Medical University,Quanzhou Fujian 362000,China)

机构地区：[1]福建医科大学附属第二医院病理科,福建泉州362000

出　　处：《中国卫生标准管理》2021年第11期69-71,共3页China Health Standard Management

摘　　要：目的评估DNA倍体分析系统检测结合HR-HPV检测在宫颈癌及癌前病变筛查中的临床意义。方法随机选取2019年1000例行宫颈活检及宫颈细胞学检查的标本,同时行DNA倍体分析系统检测和HR-HPV检测,并对结果进行统计学分析。结果CIN I及以上的阳性检出率:HR-HPV阳性率67.6%~90.9%;DNA倍体分析结果阳性率5.3%~76.4%;HR-HPV+DNA倍体分析结果阳性率70.7%~100%。结论随着组织病理恶性度升高,HR-HPV及DNA倍体分析结果阳性率都有不同程度的升高。DNA倍体分析系统结合HR-HPV检测,可以提高宫颈癌及癌前病变的检出率,有效的提高检查的准确性。Objective To evaluate the clinical significance of DNA ploidy analysis system combined with HR-HPV detection in the screening of cervical cancer and precancerous lesions.Methods 1000 samples of cervical biopsy and cervical cytology were randomly selected in 2019.DNA ploidy analysis system and HR-HPV test were performed at the same time,and the results were statistically analyzed.Results The CIN I and more positive detection rate:HR-HPV positive rate 67.6%~90.9%.The positive rate of DNA ploidy was 5.3%~76.4%.The positive rate of HR-HPV+DNA ploidy was 70.7%~100%.Conclusion With the increase of histopathological malignancy,the positive rate of HR-HPV and DNA ploidy analysis increased in different degrees.DNA ploidy analysis system combined with HR-HPV detection can improve the detection rate of cervical cancer and precancerous lesions,and effectively improve the accuracy of detection.

关 键 词：细胞DNA倍体分析系统 HR-HPV 宫颈癌 癌前筛查 罗氏Cobas 4800 阳性率 

分 类 号：R711[医药卫生—妇产科学]